Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are studying healthy infants in Indonesia to compare the immune response and safety of two vaccines Minhais 13-valent Pneumococcal Polysaccharide Conjugate Vaccine PCV13-DTTT, also called Pneuminvac and Pfizers 13-valent Pneumococcal Conjugate Vaccine PCV13, known as Prevenar 13. The study focuses on infants aged 6 to 8 weeks and aims to show that Pneuminvac produces immune responses that are not worse than Prevenar 13 after a booster dose, while also monitoring vaccine safety when given together with a hexavalent vaccine. About 500 infants will be randomly assigned to two groups one receiving Pneuminvac and the other receiving Prevenar 13. Both vaccines will be given at 2, 4, and 12 to 15 months of age. Additionally, all infants will receive the hexavalent vaccine at 2, 3, and 4 months of age. This design follows World Health Organization recommendations for infant vaccination schedules. Participants will attend scheduled visits for vaccinations and assessments, including blood tests to measure immune responses one month after the booster dose. Safety will be closely tracked by recording any side effects after each vaccine dose and serious adverse events up to six months after the booster. The study aims to evaluate the percentage of infants with protective antibody levels and compare immune responses between vaccines, with total participation lasting from enrollment until several months after the final vaccine dose.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effects of different exercise training methods on muscle structure and the prevention of Patellofemoral Pain Syndrome and Anterior Cruciate Ligament ACL injuries in sportsmen aged 15 to 35 who participate in level 1 sports such as martial arts, basketball, futsal, and soccer. This clinical trial compares low-load blood flow restriction training LL-BFRt, a sham version of LL-BFRt, and high-load eccentric training HL-Et to see which method better improves muscle morphology and reduces injury risk. Participants will be randomly assigned to one of three groups LL-BFRt, sham LL-BFRt, or HL-Et. The LL-BFRt group will perform eccentric exercises like stairs, single leg squats, and single leg deadlifts at 30% of their maximum repetition and with 70% arterial occlusion pressure applied by cuffs. The sham LL-BFRt group will do the same exercises at 30% maximum repetition but with only 10% arterial occlusion pressure. The HL-Et group will perform the exercises at 70% maximum repetition without blood flow restriction. Both treatments are guided by a physical therapist. Throughout the study, researchers will measure muscle cross-sectional area, fiber angle of the vastus medial obliques, and patella position after 8 weeks. They will also monitor the incidence of Patellofemoral Pain Syndrome and ACL injuries over one year. Participants are expected to maintain their assigned exercise regimen and provide informed consent. The study aims to understand which training method offers better muscle improvements and injury prevention in active sports participants.
Actively Recruiting
Researchers are evaluating the effectiveness of two ultrasound-guided nerve block techniques, the midpoint transverse process to pleura MTP block and the erector spinae plane ESP block, for managing postoperative pain in adults undergoing elective video-assisted thoracoscopic surgery VATS. This randomized, double-blind controlled trial compares these blocks to determine differences in pain control and recovery quality within the first 24 hours after surgery. The study is conducted at RS Ngoerah, Denpasar, Indonesia, and aims to improve pain management after minimally invasive thoracic surgery. Participants receive either the MTP block or the ESP block, both performed under general anesthesia at the T4-T5 level before surgical incision. Each block involves a single injection of 20 mL ropivacaine 0.375%. All participants receive standardized general anesthesia, intravenous ibuprofen and paracetamol before wound closure, and postoperative fentanyl patient-controlled analgesia PCA. The study uses random allocation with sealed envelopes and maintains blinding for participants and evaluators. During the study, participants are monitored for fentanyl consumption via PCA over 24 hours, pain intensity at multiple time points, time to first additional pain medication, and quality of recovery using the QoR-15 questionnaire. Assessments are done by a blinded Acute Pain Service team. Safety is closely observed for adverse events such as local anesthetic toxicity and pneumothorax. The total participation duration covers the surgery day and the first 24 hours postoperatively.
Actively Recruiting
This research aims to evaluate the effectiveness of dry needling and Low-Level Laser Microcurrent Electrical Stimulation LL MCES in adults aged 20 to 45 years with acute upper trapezius myofascial pain syndrome MPS. The study focuses on understanding if these treatments reduce inflammation and oxidative stress by measuring changes in serum tumor necrosis factor-alpha TNF- and malondialdehyde MDA levels, alongside improvements in pain and neck-related disability. This trial addresses the gap in knowledge about how these biological changes relate to clinical benefits from non-drug therapies. Participants are randomly assigned to one of four groups dry needling alone, LL MCES alone, combined dry needling and LL MCES, or sham dry needling that mimics treatment without actual needle penetration. Treatments target the upper trapezius muscles trigger points using standardized protocols. Blood samples are collected before and after the intervention to assess serum TNF- and MDA levels. Clinical assessments of pain intensity and neck disability are also completed before and after treatment. During the study, participants attend scheduled follow-up visits for clinical evaluation and outcome measurement. Researchers use the Numerical Pain Rating Scale NPRS and Neck Disability Index NDI to gauge pain and function. Safety and adherence are monitored throughout. The primary outcomes include changes in serum MDA and TNF- concentrations measured at baseline and three days after treatment completion. The total participation period extends from treatment through follow-up assessments.
Actively Recruiting
Carpal Tunnel Syndrome CTS is caused by pressure on the median nerve in the wrist, leading to pain, numbness, tingling, and reduced hand function. This trial examines how adding amniotic membrane combined with secretome to standard carpal tunnel release surgery affects symptom relief and nerve recovery in adults with moderate-to-severe CTS. The study is a randomized controlled trial comparing surgery alone to surgery plus these biological treatments, using clinical and nerve tests to evaluate results. Participants will be randomly assigned to one of three groups standard carpal tunnel release surgery, surgery with amniotic membrane applied to the median nerve, or surgery with amniotic membrane soaked in secretome solution applied to the nerve. The amniotic membrane used measures 10 mm by 10 mm and is applied during surgery. Secretome is soaked onto the membrane for one minute before placement. The study focuses on treatments delivered during the surgical procedure. Participants will be assessed before surgery and again three weeks after the procedure. Evaluations include the Boston Carpal Tunnel Questionnaire BCTQ to measure symptoms and hand function, and electromyography EMG to assess nerve regeneration. The study is double-blinded and sponsored by PT. Prodia Stem Cell Indonesia. Participants are expected to comply with study procedures and provide informed consent, with total follow-up lasting at least three weeks post-surgery.
Actively Recruiting
This research aims to understand acute malnutrition in infants younger than 6 months admitted to pediatric or perinatology wards in hospitals across Indonesia. The study will observe how common acute malnutrition is in this age group and investigate the outcomes of nutrition therapy, including recovery, growth improvement, complications, and death. It also seeks to identify factors linked to successful nutrition treatment based on the 2023 WHO criteria. The study is observational and will not provide experimental treatments. Instead, it will collect detailed measurements of infants weight, length, head circumference, and mid-upper arm circumference at baseline, day 3, day 7, and weekly until hospital discharge. Information about birth history, feeding, illnesses, and nutrition therapy provided by treating doctors will be recorded. Data will be securely stored in a shared electronic database to ensure consistency across multiple hospitals participating in the network. Participants will be infants under 6 months diagnosed with acute malnutrition. Researchers will gather clinical data, anthropometric measurements, feeding details, and lab results during hospital stay. The study will monitor nutritional status changes up to 24 weeks or until discharge and track outcomes such as mortality. Results will help develop evidence-based feeding guidelines and improve clinical care for malnourished infants in Indonesia.
Actively Recruiting
Researchers are evaluating the effects of two different carbohydrate drinks on stomach fluid volume and blood markers in patients aged 60 years and older undergoing elective lower limb orthopedic surgery under spinal or epidural anesthesia. The study aims to determine which drink, maltodextrin or sugar water, is better suited to improve safety and comfort during pre-surgery fasting in older adults. This investigation is a randomized, double-blind trial conducted at Prof. Ngoerah General Hospital in Denpasar, Indonesia. Participants are randomly assigned to drink 400 mL of either a maltodextrin carbohydrate drink or sugar water within 15 to 30 minutes, two hours before anesthesia, following a 6-hour fast from solid food. The drinks are served in identical opaque containers to maintain blinding. The study measures stomach fluid volume by ultrasound before and two hours after drinking, as well as blood glucose levels before drinking, two hours after, and six hours after surgery. Additionally, blood samples assess inflammatory stress markers before surgery and six hours postoperatively. During the study, participants undergo baseline assessments of physical measurements, blood glucose, and blood counts. Gastric ultrasound and glucose testing are repeated after drink consumption and surgery. Data on surgery type, duration, and blood loss are also collected. Safety is monitored for any adverse events including allergy or nausea. The primary outcome is the stomach fluid volume two hours after drink intake, with secondary outcomes including changes in blood glucose and inflammatory markers. Total participation involves the day before surgery through six hours after surgery.
Actively Recruiting
Researchers are comparing two injection treatments, secretome and intradermal platelet-rich plasma PRP, to see how they affect hair density and the ratio of terminal to vellus hairs in people with androgenetic alopecia. This randomized controlled clinical study takes place at Prof. Dr. I.G.N.G. Ngoerah General Hospital and focuses on adults aged 25 to 59 years with specific stages of hair loss. The purpose is to evaluate which treatment better supports hair growth and density. Participants receive either umbilical cord mesenchymal stem cell-derived secretome or platelet-rich plasma injections. Both treatments involve intradermal injections spaced 1 cm apart at the alopecia site and are administered every 2 weeks for a total of 8 weeks. The secretome and PRP injections are given under controlled conditions, with patients randomly assigned to one of the two groups. During the study, hair density and the terminal-to-vellus hair ratio are measured before treatment, at 8 weeks after intervention, and again during follow-up visits at months 3, 6, and 9. Evaluations use trichoscopy or dermoscopy to monitor changes. Participants provide informed consent and are monitored throughout the study to track treatment effects and safety. The total study duration includes treatment and follow-up periods to assess long-term outcomes.